THE STREET 11/27
Galena has had no luck attracting a partner, a buyer or institutional investors despite heavy promotional efforts all year. Insiders haven't been buying their own stock either. With less than $15 million in the bank, at least one dilutive financing in 2013 is likely. The best days for Galena are in the rear-view mirror already.
The most salient part of the post is the lack of institutional investors. Couple that with the fact that GALE has NO big pharma partnerships or interest does not bode well for any future success. I've held this stock since inception and have run out of patience and hope that it has any kind of positive future.
It plummeted to $1.40 because its a small company without a huge pipeline and during the downtime between results it inevitably dips. MICROMET did the same thing, and now their drug Blimatumomab is going change leukemia treatment and the company got sold for $1.2 billion and the stock went from $2 to $11 when AMGEN bought it.
Sentiment: Strong Buy
I had MITI about a year and sold when they announced the sale to AMGN. I've been in GALE a few months and this drug is going to be a game changer for breast cancer. It will be worth multi billions!